Evidence map›Paper›PMID 24586797›Full record

ArticlePloS one2014

PIAS1 regulates breast tumorigenesis through selective epigenetic gene silencing.

Bin Liu, Samuel Tahk, Kathleen M Yee, Randy Yang, Yonghui Yang, Ryan Mackie, Cary Hsu, Vasili Chernishof, Neil O'Brien, Yusheng Jin and 5 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in PloS one, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.

0numbers the graph read from it
0cells of the map it votes in
25citing papers in PubMed
2.1field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

25 citing papers in PubMed, 36 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Cancer-Associated Dysregulation of Sumo Regulators: Proteases and Ligases.International journal of molecular sciences · 2022
    Review
  5. Review
  6. SUMOylation and NEDDylation in Primary and Metastatic Cancers to Bone.Frontiers in cell and developmental biology · 2022
    Review
  7. Article
  8. Review
  9. Review
  10. Review
  11. Review
  12. Article
  13. Review
  14. Article
  15. Article
  16. SUMO and the robustness of cancer.Nature reviews. Cancer · 2017
    Review
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 1 institution in 1 country.

Bin LiuDivision of Hematology-Oncology, Department of Medicine, University of California Los Angeles, Los Angeles, California, United States of America.
Samuel TahkDivision of Hematology-Oncology, Department of Medicine, University of California Los Angeles, Los Angeles, California, United States of America.
Kathleen M YeeDepartment of Biological Chemistry, University of California Los Angeles, Los Angeles, California, United States of America.
Randy YangDepartment of Biological Chemistry, University of California Los Angeles, Los Angeles, California, United States of America.
Yonghui YangDivision of Hematology-Oncology, Department of Medicine, University of California Los Angeles, Los Angeles, California, United States of America.
Ryan MackieDivision of Hematology-Oncology, Department of Medicine, University of California Los Angeles, Los Angeles, California, United States of America.
Cary HsuDepartment of General Surgery, University of California Los Angeles, Los Angeles, California, United States of America.
Vasili ChernishofDivision of Hematology-Oncology, Department of Medicine, University of California Los Angeles, Los Angeles, California, United States of America.
Neil O'BrienDivision of Hematology-Oncology, Department of Medicine, University of California Los Angeles, Los Angeles, California, United States of America.
Yusheng JinDepartment of Pathology and Laboratory Medicine, University of California Los Angeles, Los Angeles, California, United States of America.
Guoping FanDepartment of Human Genetics, University of California Los Angeles, Los Angeles, California, United States of America.
Timothy F LaneDepartment of Obstetrics and Gynecology, University of California Los Angeles, Los Angeles, California, United States of America.
Jianyu RaoDepartment of Pathology and Laboratory Medicine, University of California Los Angeles, Los Angeles, California, United States of America.
Dennis SlamonDivision of Hematology-Oncology, Department of Medicine, University of California Los Angeles, Los Angeles, California, United States of America.
Ke ShuaiDivision of Hematology-Oncology, Department of Medicine, University of California Los Angeles, Los Angeles, California, United States of America ; Department of Biological Chemistry, University of California Los Angeles, Los Angeles, California, United States of America.
University of California, Los Angeles · US

Funding

Women's CancersP30CA016042 · NCI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI Samuel Wheeler French · 1985 to 2026
$134.5M
The Role of PIAS1 in Immune RegulationR01AI063286 · NIAID · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI LIU, BIN, SHUAI, KE · 2005 to 2017
$3.3M
Signaling to PIAS1 to Regulate Immune ResponsesR01GM085797 · NIGMS · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI SHUAI, KE · 2008 to 2011
$1.2M
The role of PIAS1 in inflammation and immune disordersK01AR052717 · NIAMS · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI LIU, BIN · 2006 to 2010
$643k
NCI NIH HHS P30 CA016042NIAID NIH HHS R01 AI063286NIAID NIH HHS R01AI063286NIAMS NIH HHS K01 AR052717NIAMS NIH HHS K01 AR52717-01NIGMS NIH HHS R01 GM085797NIGMS NIH HHS R01GM085797
6 · The paper itself

Abstract

Epigenetic gene silencing by histone modifications and DNA methylation is essential for cancer development. The molecular mechanism that promotes selective epigenetic changes during tumorigenesis is not understood. We report here that the PIAS1 SUMO ligase is involved in the progression of breast tumorigenesis. Elevated PIAS1 expression was observed in breast tumor samples. PIAS1 knockdown in breast cancer cells reduced the subpopulation of tumor-initiating cells, and inhibited breast tumor growth in vivo. PIAS1 acts by delineating histone modifications and DNA methylation to silence the expression of a subset of clinically relevant genes, including breast cancer DNA methylation signature genes such as cyclin D2 and estrogen receptor, and breast tumor suppressor WNT5A. Our studies identify a novel epigenetic mechanism that regulates breast tumorigenesis through selective gene silencing.

Indexed as

AnimalsBreastBreast NeoplasmsCarcinogenesisCell Line, TumorCyclin D2DNA MethylationEpigenesis, GeneticFemaleGene Expression Regulation, NeoplasticGene SilencingHumansMice, SCIDProtein Inhibitors of Activated STATProto-Oncogene ProteinsReceptors, EstrogenCCND2 protein, humanCyclin D2PIAS1 protein, humanProtein Inhibitors of Activated STATProto-Oncogene ProteinsReceptors, EstrogenSmall Ubiquitin-Related Modifier ProteinsUbiquitin-Protein LigasesWnt-5a ProteinWNT5A protein, humanWnt Proteins

Identifiers

PMID24586797
PMCPMC3933565
OpenAlexW1963845413

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.